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Abstract
Background: Elevated stearoyl-CoA desaturase activity has been described in obese states, with an increased
desaturation index (DI) suggesting enhanced lipogenesis. Differences in the DI among various phenotypes of abnormal
adiposity have not been studied. Abnormal accumulation of subcutaneous adipose tissue occurs in rare adipose disorders
(RADs) including Dercum’s disease (DD), multiple symmetric lipomatosis (MSL), and familial multiple lipomatosis (FML).
Examining the DI in subcutaneous fat of people with DD, MSL and FML may provide information on adipose tissue fatty
acid metabolism in these disorders. The aims of this pilot study were: 1) to determine if differences in adipose tissue DIs
are present among RADs, and 2) to determine if the DIs correlate to clinical or biochemical parameters.
Methods: Subcutaneous adipose tissue was obtained from human participants with DD (n = 6), MSL (n = 5), FML
(n = 8) and obese Controls (n = 6). Fatty acid composition was determined by gas chromatography/mass
spectrometry. The DIs (palmitoleic/palmitic, oleic/stearic, vaccenic/stearic ratios) were calculated from the gas
chromatogram peak intensities. SCD1 gene expression was determined. Spearman’s correlations between the DIs
and available clinical or biochemical data were performed.
Results: In DD subjects, the vaccenic/stearic index was lower (p < 0.05) in comparison to Controls. Percent of total
of the saturated fatty acid myristic acid was higher in DD compared with Controls and FML. Percent of
monounsaturated vaccenic acid in DD trended lower when compared with Controls, and was decreased in
comparison to FML. In MSL, total percent of the polyunsaturated fatty acids was significantly lower than in the
Control group (p < 0.05). In the total cohort of subjects, the palmitoleic/palmitic and oleic/stearic DIs positively
correlated with age, BMI, and percent body fat.
Conclusions: The positive associations between the DIs and measures of adiposity (BMI and percent body fat)
support increased desaturase activity in obesity. The lower vaccenic/stearic DI in DD SAT compared with Controls
suggests presence of other factors involved in fat accumulation in addition to lifestyle. Other mechanisms driving
fat accumulation in DD such as inflammation or lymphatic dysfunction should be investigated.
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Background
Altered fatty acid metabolism has been implicated in the
development of obesity. Elevated fatty acid desaturase
activity by determination of the desaturation index is
being studied as a potential biomarker of metabolic risk.
Saturated fatty acids (SFA) made by de novo synthesis
o rt a k e nu pf r o mt h ed i e ta r ec o n v e r t e dt od e l t a - 9
monounsaturated fatty acids (MUFA) by stearoyl-CoA
desaturase enzyme 1 (SCD1), a membrane-bound
enzyme highly expressed in the liver and adipose tissue.
The desaturation index (DI) is the ratio of MUFA pro-
duct to SFA precursor, and is a measure of SCD1 activ-
ity since it has been shown to correlate with SCD1 gene
expression, protein expression, and enzyme activity [1,2].
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proinflammatory settings of Crohn’s disease and coron-
ary artery disease [3-5]. Increased SCD1 activity has
been demonstrated in obese states [2,6,7] with correla-
tion to other markers of abnormal metabolism [8].
However, whether variations in desaturase activity exist
among different obese phenotypes has not been suffi-
ciently investigated, and we applied this question to the
study of human subjects with rare adipose disorders
(RADs) (Table 1).
RADs involve the abnormal formation of fatty masses
in the subcutaneous adipose tissue (SAT). RADs include
Dercum’s disease (DD), multiple symmetric lipomatosis
(MSL) and familial multiple lipomatosis (FML). These
disorders differ in whether or not pain is present and in
the location of fatty masses [10,16,19]. The pathophysiol-
ogy of RADs is believed to be different from the general-
ized accumulation of fat in obesity because the abnormal
SAT follows discrete patterns, can occur in both obese
and non-obese individuals [10,20], may include loss of
normal fat (as in MSL)[21], and may involve alterations
of the lymphatic system [21,22]. A previous study sug-
gested that inflammation is involved in the selective
expansion of the adipose tissue in DD through elevated
interleukin IL-6 expression in affected SAT, and
increased blood IL-13 levels in DD women compared to
controls [23]. However, another study found no differ-
ence in the number of perivascular immune cells in the
painful SAT of women with DD in comparison to the
non-painful SAT of a subset of these women, and in
comparison to the SAT samples from healthy, pain-free,
obese and normal weight control subjects [24].
Previous data on fatty acid analyses from DD SAT
compared to normal adipose tissue is limited. However,
available data suggests that the formation of 18-carbon
fatty acids, particularly desaturation of stearic (18:0) to
oleic (18:1) acid may be blocked in DD (decreased desa-
turation) [25]. More recent work, however, suggests an
elevation in MUFA in the DD SAT (increased desatura-
tion) [26] compared to non-obese controls. There is lit-
tle available data on fatty acid composition in FML and
MSL. However, one study suggested elevated monounsa-
turated palmitoleic acid in SAT of MSL subjects [27].
The objectives of this study were 1) to determine if
differences in adipose tissue DIs are present among var-
ious phenotypes of obesity, and 2) to determine if the
adipose tissue DIs correlate to biochemical or clinical
parameters. We hypothesized that differences in the
fatty acid profiles and DIs exist between the RAD
groups and obese controls. We also hypothesized that
the DIs correlate to clinical measures of adiposity, and
that the correlation patterns may differ between groups.
We determined the fatty acid profiles and desaturation
indices in DD, FML, and MSL in comparison to obese
Controls using gas chromatography/mass spectrometry
(GC/MS), and examined correlation patterns between
the desaturation indices and biochemical or clinical
parameters.
Results
Subjects
Subject demographics are presented in Table 2. There
were no significant differences between groups for age
or body mass index (BMI). There were more women in
Table 1 Rare adipose disorders and their clinical features
Disorder Synonym Pattern of Abnormal SAT Clinical Features
Dercum’s disease
(DD) [9]
Type I
Type II
Type III
Adiposis
dolorosa
Morbus
Dercums
Type I: Juxta-articular
Type II: Diffuse, associated with obesity
Type III: Discrete, fatty lumps
Painful subcutaneous adipose tissue in
all types
Male-female ratio 1:5-30
Fatigue, myalgias, shortness of breath
[10]
Autosomal dominant transmission has
been reported [11]
Familial multiple
lipomatosis (FML)
None Discrete, lipomas +/- encapsulation; arm, thighs, abdomen, lower
back, flanks [12,13]
Non-painful.
Male-female ratio 1:1
If lipomatosis becomes painful, is
considered DD Type III [11,14,15].
Autosomal dominant transmission;
recessive inheritance has been
reported.
Multiple symmetric
lipomatosis (MSL)
Lanois-
Bensaude’s
syndrome
Benign
symmetric
lipomatosis
Madelung’s
disease
Diffusely in men on neck and back, upper arms in women;
supraclavicular, on abdomen, and lower back in both men and
women [16]
Non-painful.
Male-female ratio 15:1-30:1
Polyneuropathy [17]
Mitochondrial mutations found in
some [18]
Risk factors: corticosteroids and
alcohol abuse.
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Page 2 of 11the DD and MSL groups and more men in the FML
group compared to Controls.
Fatty acids
Table 3 lists the fatty acids in the order of elution on
the gas chromatogram. Nine major chromatogram
peaks, each representing a different fatty acid, were
observed in all samples from RAD and Control subjects,
except for arachidonic acid, which was not detected in
one DD subject and one FML subject. These nine peaks
corresponded to myristic, palmitic, palmitoleic, stearic,
oleic, vaccenic, linoleic, a-linolenic, and arachidonic
acids. Three additional peaks (designated by ¥) were
detectable in less than half of the subjects so compari-
sons were not made between groups, but are included
in Table 3 for interest. Two of these peaks are referred
to as 18:1X and 18:1Y, due to the general inability to
determine position of the double bond by GC/MS, and
the third peak was thought to be eicosenoic acid. Eico-
sapentaenoic acid (EPA, 22:5) and docosahexaenoic acid
(DHA, 22:6) were undetectable in the study subjects.
The saturated myristic acid percent of total was signif-
icantly higher in DD than in the Control (p < 0.01) and
FML groups (p < 0.05). The monounsaturated vaccenic
Table 2 Subject demographics, and BMI.
Group
Control (n = 6) DD (n = 6) FML (n = 8) MSL (n = 5)
Age (years) 49.0 (42.0-58.0) 46.5 (40.0-52.0) 38.5 (37.5-46.5) 50.0 (40.3-50.3)
Males/females (n) 4M/2F 2M/4F 6M/2F 1M/4F
BMI (kg/m
2) 34.7 (32.2-38.1) 29.2 (28.0-35.0) 30.5 (27.3-32.0) 32.1 (31.8-46.5)
The median is presented with the 25-75% interquartile ranges
DD Dercum’s disease, FML Familial multiple lipomatosis, MSL Multiple symmetric lipomatosis
Table 3 Subject fatty acid profiles.
Group
Control (n = 6) DD (n = 6) FML (n = 8) MSL (n = 5)
Saturated and Monounsaturated Fatty Acids Percent of Total (SEM)
14:0 (myristic) 1.22 (1.17-1.38) 1.74 (1.52-1.78)**† 1.30 (1.08-1.47) 1.53 (1.12-2.29)
16:0 (palmitic) 27.4 (24.8-28.5) 27.3 (26.0-29.2) 25.4 (25.2-28.3) 26.3 (23.0-31.6)
16:1n-7 (palmitoleic) 3.68 (2.90-4.04) 2.78 (2.18-3.43) 2.71 (2.27-3.28) 4.04 (3.24-4.95)
18:0 (stearic) 4.15 (3.93-5.52) 6.07 (5.81-7.92) 5.80 (5.59-7.21) 3.88 (2.21-7.72)
18:1X
¥ 1.95 (1.87-2.54) 1.52 (1.12-1.92) 1.91 (1.43-2.01) 1.71 (1.27-2.14)
18:1n-9 (oleic) 47.8 (46.1-48.9) 48.5 (47.5-49.0) 48.2 (46.9-48.7) 46.6 (43.3-51.9)
18:1n-7 (vaccenic) 3.22 (2.72-5.70) 2.01 (1.72-2.61)†‡ 5.85 (4.09-6.25) 2.95 (2.64-6.31)
18:1Y
¥ 0.82 (0.75-0.94) not detected 2.22 (2.05-2.38) 0.82 (N/A)
20:1n-9
(eicosenoic)
¥
0.65 (0.60-0.73) 0.60 (0.52-0.72) 0.70 (0.62-0.79) 0.50 (0.49-0.54)
Total percent SFA 33.4 (29.1-34.8) 36.2 (35.7-38.6) 33.0 (31.1-35.5) 31.3 (26.6-41.7)
Total percent MUFA 57.9 (54.8-59.8) 54.4 (53.5-56.2) 57.0 (55.2-60.2) 56.4 (53.1-61.0)
Polyunsaturated Fatty Acids Percent of Total (SEM)
18:2n-6
(linoleic, LA)
9.12 (8.31-10.4) 8.34 (8.10-8.89) 9.65 (8.07-9.94) 5.64 (4.61-8.50)‡
18:3n-3
(a-linolenic, ALA)
0.23 (0.17-0.26) 0.24 (0.18-0.32) 0.21 (0.17-0.26) 0.15 (0.12-0.17)‡†
20:4n-6 (arachidonic, AA) 0.13 (0.10-0.16) 0.10 (0.09-0.13) 0.13 (0.11-0.20) 0.14 (0.13-0.41)
#
Total percent PUFA (LA+ALA+AA) 9.49 (8.58-10.8) 8.61 (8.31-9.29) 10.0 (8.35-10.3) 6.21 (5.07-8.80)*
n-6/n-3 ratio (LA+AA)/ALA
(arbitrary units)
43.3 (40.1-50.4) 36.8 (29.2-47.1) 44.6 (37.7-51.4) 40.1(30.5-50.3)
The median percent of total is presented with the 25-75% interquartile range in parentheses. In DD, myristic acid percent of total is increased compared to
Controls and FML. Vaccenic acid percent of total trends toward a decrease compared to Controls, but is significantly lower compared to FML
DD Dercum’s disease, FML Familial multiple lipomatosis, MSL Multiple symmetric lipomatosis
*p < 0.05 vs. Control; **p < 0.01 vs. Control; †p < 0.05 vs. FML; ‡ trended lower vs. Control (see text);
#trended higher vs.DD;
¥no comparison between groups made due to low prevalence in the groups; N/A non-applicable because not detected in enough
subjects to provide a value
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and was significantly decreased compared to FML (p <
0.05). The abundance of linoleic acid (LA) trended
lower in MSL versus the Control (p =0 . 0 5 )a n dF M L
groups. The a-linolenic acid (ALA) percent of total in
MSL trended lower in comparison to Controls (p =
0.05), but was significantly lower when compared to
FML (p < 0.05). Arachidonic acid (AA) trended higher
in the MSL group compared with DD. The sum percent
of total of the detected PUFA was significantly lower in
MSL (p < 0.05), and trended lower in DD, compared
with Controls.
Desaturation and elongation indices
The oleic/stearic DI in the DD group trended lower ver-
sus the Control group (Table 4). The DI for vaccenic/
stearic was significantly lower in the DD group com-
pared to Controls (p < 0.05) and when compared to the
FML group (p < 0.01). There was no difference in the
palmitoleic/palmitic DI among the groups. The (palmi-
toleic + vaccenic)/palmitic DI for the DD group trended
lower compared to the Control group, and was
decreased in comparison to the FML group (p < 0.05).
There were no differences among the groups for the
stearic/palmitic elongation index.
Adipose tissue expression of SCD-1
The RNA was of good quality and the cDNA performed
well when tested with reference genes (data not shown).
SCD-1 gene expression was below the limits of detec-
tion in all groups, including obese Control subjects
(data not shown).
Correlations between fatty acid indices and clinical or
biochemical parameters
Adipose tissue samples were obtained from two different
studies, therefore the biochemical data and measure-
ments were incomplete. The data and number of
subjects for each measure are presented in Table 5. In
the total cohort of subjects, the palmitoleic/palmitic,
oleic/stearic, vaccenic/stearic, (palmitoleic + vaccenic)/
palmitic DI all correlated positively with each other, and
negatively with the stearic/palmitic ratio. Age positively
correlated with palmitoleic/palmitic (r = 0.51, p < 0.05)
and the oleic/stearic DI (r = 0.48, p <0 . 0 5 ) .B M Ia l s o
positively correlated with the palmitoleic/palmitic (r =
0.40, p < 0.05) and the oleic/stearic DI (r = 0.44, p <
0.05) (Figure 1), but was negatively correlated with the
stearic/palmitic ratio (r = -0.59, p < 0.01). Percent body
fat was positively associated with the palmitoleic/palmi-
tic (r = 0.51, p < 0.05) and oleic/stearic DI (r = 0.58, p <
0.05, Figure 2), and negatively associated with the stea-
ric/palmitic ratio (r = -0.57, p < 0.05). Among females,
percent body fat correlated with the oleic/stearic DI (r =
0.83, p < 0.01). Among males, percent body fat corre-
lated with both the palmitoleic/palmitic DI (r = 0.86, p
< 0.01) and the oleic/stearic DI (r = 0.79, p <0 . 0 5 ) .A
correlation pattern could not be confirmed within RAD
and Control groups due to small subject numbers.
The oleic/stearic, vaccenic/stearic, and (palmitoleic +
vaccenic)/palmitic acid DI correlated negatively with
adiponectin (r = -0.82, p < 0.01; r = -0.80, p <0 . 0 1 ;r=
-0.78, p < 0.01 respectively) while the stearic/palmitic
elongation index correlated positively (r = 0.88, p <
0.001). No associations were found between leptin and
the DI.
Discussion
For the first time, the fatty acid composition and desa-
turation indices are presented in three RADs compared
with obese Controls. We hypothesized that fatty acid
composition may be different if the SAT developed in a
person with a RAD, with the fatty acid profile reflecting
changes in desaturase activity. Fatty acid DIs reflect the
proportion of MUFA product generated from the SFA
precursor and is known to be upregulated in models of
Table 4 The desaturation indices and the elongation index.
Index Group
Control (n = 6) DD (n = 6) FML (n = 8) MSL (n = 5)
Desaturation Index
palmitoleic/palmitic 0.13 (0.12-0.14) 0.09 (0.08-0.14) 0.11 (0.08-0.13) 0.13 (0.11-0.25)
oleic/stearic 11.4 (8.5-12.4) 7.8 (6.2-8.5)‡ 8.4 (6.5-9.7) 13.2 (5.8-21.1)
vaccenic/stearic 0.86 (0.66-1.34) 0.33 (0.22-0.46)*† 0.81 (0.72-1.37) 0.58 (0.38-3.26)
(palmitoleic+vaccenic)/palmitic 0.27(0.23-0.34) 0.18 (0.15-0.21)†‡ 0.34 (0.27-0.36) 0.37 (0.20-0.43)
Elongation Index
stearic/palmitic 0.18 (0.15-0.25) 0.22 (0.20-0.30) 0.24 (0.19-0.27) 0.15 (0.10-0.24)
Fatty acid ratios are presented as the median in arbitrary units with the 25-75% interquartile range in parentheses. DD demonstrates a decrease in the vaccenic/
stearic ratio in comparison to Controls and FML
DD Dercum’s disease, FML Familial multiple lipomatosis, MSL Multiple symmetric lipomatosis
*p < 0.05 vs. Control; †p < 0.05 vs. FML; ‡ trended lower vs. Control (see text)
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Page 4 of 11obesity, indicating enhanced lipogenesis [2,7,28]. We
demonstrate in this study that the vaccenic/stearic DI in
SAT from participants with DD, was lower than that of
obese Controls, suggesting that the SAT in DD is a bio-
chemically distinct subtype of SAT.
A contributing factor to the differences in the DIs was
a trend to decreased vaccenic acid percent of total in
the DD group compared to Controls, and a significant
decrease in comparison to the FML group. FML is char-
acterized by abnormal accumulation of SAT but not
Table 5 Clinical and biochemical parameters in the total cohort.
Clinical or biochemical parameter (units, number of subjects) Median value (25-75% interquartile range)
Age (years, n = 25) 47 (39-51)
BMI (kg/m
2, n = 25) 32.0 (29.2-35.3)
Percent body fat (%, n = 16) 35.7 (30.7-43.0)
Total cholesterol (mg/dL, n = 22) 188 (174-201)
LDL (mg/dL, n = 19) 114 (100-132)
HDL (mg/dL, n = 19) 53 (38-56)
Triglycerides (mg/dL, n = 22) 122 (98-160)
Leptin (ng/mL, n = 9) 13.9 (4.9-32.7)
Adiponectin (μg/mL, n = 9) 27.4 (12.5-32.2)
Non-esterified fatty acids (mmol/L, n = 14) 0.53 (0.38-0.75)
The values are presented as the median with the 25-75% interquartile range
BMI (kg/m2)
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Figure 1 BMI versus the oleic/stearic DI in the total cohort of subjects. There was a positive correlation between BMI and the oleic/stearic
DI, r = 0.44, p < 0.05.
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Page 5 of 11pain. It remains unclear whether the demonstrated dif-
ferences are related to presence or absence of pain.
Although the palmitoleic/palmitic acid DI was not sig-
nificantly decreased in DD subjects, the vaccenic/stearic
acid DI was decreased. Vaccenic acid is actually derived
through chain elongation of palmitoleic acid and is not
made by direct desaturation of stearate [29]. The ratio
of (palmitoleic + vaccenic)/palmitic acid was determined
to better represent the product/precursor relationships
of this pathway, and there was a decrease in this ratio in
DD subjects compared to FML, and a trend toward a
decrease in DD compared to obese Controls. This
decrease suggests a dysregulation in desaturation in DD,
in which the palmitic to palmitoleic acid desaturation
pathway is relatively suppressed, leading to decreased
elongation to vaccenic acid. These findings appear con-
sistent with a previous report on two DD subjects that
demonstrated decreased acetate-1-
14 C incorporation
during MUFA synthesis in affected adipocytes compared
to unaffected adipocytes in one subject, and decreased
18-carbon fatty acid production in the affected adipo-
cytes of the second subject [25]. The new fatty acid pro-
duction in the first subject, as measured by
incorporation of
14 C, was diminished in the 18:1 fatty
acids, but the analysis did not distinguish between oleic
and vaccenic acids. A more recent study [26] reported
increased proportions of 18:1 fatty acid percent of total
in 13 DD subjects in comparison to controls, but the
control subjects were healthy and leaner with an average
B M Io fo n l y2 6k g / m
2 while the DD subjects averaged
33.5 kg/m
2. It is unknown how the DI of our study sub-
jects would compare to those of non-obese controls or
to unaffected adipose tissue from the same subjects.
However, in many individuals with DD, MSL and FML,
all SAT tissue is affected, making an intra-person com-
parison of SAT very difficult. Nevertheless, our data
supports decreased desaturation in DD SAT compared
to SAT of other obesity phenotypes.
We were unable to identify changes in SCD1 gene
expression in our samples. Possible explanations for low
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Figure 2 Percent body fat versus the oleic/stearic DI in the total cohort of subjects. There was a positive correlation between percent
body fat and the oleic/stearic DI, r = 0.58, p < 0.05. This association was present in both males and females.
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enzyme turnover. Altered protein expression and/or
enzyme activity are potential causes of changes in the
desaturation indicies in the absence of changes in gene
expression. Discordant SCD1 mRNA and protein
expression has been demonstrated in adipose tissue
from obese humans [30]. These possibilities were not
able to be explored within the scope of the present
study and should be investigated in the future.
A lower desaturation index or a shift towards
increased saturated fatty acids has been associated with
inflammatory states. SCD1-deficient mice are protected
against diet-induced obesity, however, they have
increased plasma inflammatory markers and increased
risk for atherosclerosis [31]. In a mouse model of colitis,
fatty acid constituents of lysophosphatidylcholines were
shifted towards increased saturated species relative to
monounsaturated species, consistent with deceased
SCD1 expression levels in the liver [4]. In patients with
coronary artery disease, epicardial fat exhibits higher
SFA, lower unsaturated fatty acids, and secretes more
proinflammatory cytokines than SAT [5]. Induction of
the adipocyte immune response by saturated fatty acids
has been proposed to be mediated through the toll-like
receptor-4/NFkB pathway [32]. In addition, adipose tis-
sue can hypertrophy near areas of inflammation such as
infected lymph nodes [33] or inflamed tissues [3].
Although obesity is associated with a low-grade, chronic
inflammation in the adipose tissue, DD adipose tissue
exhibits increased expression of IL-6 mRNA and evi-
dence of pro-inflammatory macrophages, even in com-
parison to BMI- and weight-matched obese controls
[23]. Decreased desaturation leads to decreased turnover
of proinflammatory saturated fatty acids [34], and we
see in our DD subjects an increased proportion of satu-
rated myristic acid in comparison to Controls. A possi-
ble relationship between DD fatty acid metabolism and
inflammation in our subjects should be further investi-
gated as others found no evidence of increased inflam-
mation in the DD SAT based on counting primarily
perivascular immune cells in the DD SAT compared to
controls [24]. An alternative explanation, that the lower
DI in DD SAT reflects lower caloric intake cannot be
dismissed but is less likely due to the presence of
increased SAT in DD.
Additional contributing factors to inducing SAT
growth other than lifestyle and inflammation have been
reported. In mice with Prox1 haploinsufficiency, leakage
of lymphatic fluid induced growth of fat [35]. Lymph
can be a strong inducer of adipogenesis. It is interesting
to note that manual lymphatic drainage decreased the
amount of fat in a case of DD [36]. In a study on lipo-
mas, increased lipoprotein lipase activity was implicated
in the development of the abnormal adipose tissue
masses [37].
With respect to PUFA, a low percent of total PUFA in
MSL and a lower trend in DD were observed in com-
parison to obese controls. n-6 and n-3 PUFAs have
been considered as anti-inflammatory fatty acids, with
n-3 PUFAs having more potent anti-inflammatory
effects. PUFA-deficiency may lead to consideration of
whether inflammation is present in MSL. However, the
DIs were not decreased in MSL. While LA trended
lower in MSL, its downstream product AA trended
higher than in DD, suggesting decreased AA turnover.
AA is further metabolized to eicosanoids which can be
either inflammatory or proinflammatory, so the signifi-
cance of increased AA in MSL compared to DD is
uncertain. An assessment of affected fat in MSL after
intervention with dietary PUFAs (such as those found in
fish oil) may be performed to determine the clinical sig-
nificance of PUFA deficiency in MSL. In contrast, no
clinical signs or studies in FML have suggested an
inflammatory component in the development of the
abnormal SAT in this RAD to date, and the cause for
the growth of the hundreds of fatty nodules in this dis-
order remains unknown.
The relationships between desaturase activity and clin-
ical markers of metabolic risk have yet to be deter-
mined. Although there were no differences that could
be discerned in the correlations between clinical data
and the palmitoleic/palmitic and oleic/stearic DI
between groups, both DI were found to be correlated
with the BMI and percent body fat in the total cohort.
This is consistent with data showing that the DI in adi-
pose tissue of obese mice are associated with BMI and
the adiposity index [28]. The plasma DI has also been
previously described as correlating to waist circumfer-
ence in adults [7] and to the waist-hip ratio in adoles-
cents [38]. Larger numbers of subjects in each of our
study groups would be necessary to draw conclusions
about whether any group differs in strength of associa-
tion from the others, and to assess the influence of age
and gender.
Although we were limited by availability of data on
adiponectin, we found negative correlations between
adiponectin levels and the oleic/stearic acid, vaccenic/
stearic, and the (palmitoleic + vaccenic)/palmitic acid
DI. An association between desaturase activity and adi-
ponectin would be consistent with previously published
data that demonstrated an inverse association between
the plasma oleic/stearic DI and adiponectin in adoles-
cent girls [8]. In Crohn’s disease patients, mesenteric
adipose tissue has been found to exhibit more saturated
fatty acids [3,39], and a separate study showed increased
adiponectin expression [40].
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in the groups, lack of adipose tissue samples from a
non-obese control group, and limited clinical and bio-
chemical data. Subject numbers in the groups are small
due to the rarity of these adipose disorders, and there-
fore the ability to examine correlations within groups is
limited. Complete anthropometric data to assess degree
of adiposity, as well as insulin resistance measures,
would also have been desirable. Adipose tissue samples
were also of insufficient quantity to perform protein
expression studies or enzyme activity assays. Further
studies are needed to explore the potential relationships
between adipose tissue desaturase activity, inflammation,
and other lipid parameters in people with and without
RADs.
Increased SCD1 activity has been implicated not only
in obesity, but also in the associated disorders of insulin
resistance [41] and fatty liver [42]. Moreover, SCD1
activity may affect cell signaling processes through
changes in the proportion of MUFA to SFA in cell
membranes, and its role in cell proliferation and cancer
is being investigated. Recent studies have implicated
upregulation of SCD1 in lung cancer [43], prostate can-
cer [44], and breast cancer [45]. Pharmacologic inhibi-
tion of SCD1 has demonstrated a decrease in the
MUFA/SFA ratio and cell proliferation in lung cancer
cells [43], and has blocked signaling processes involved
in oncogenesis and cancer progression in prostate can-
cer cells [44]. Therefore, SCD1 is emerging as an
enzyme with diverse biological roles and requires further
investigation.
Conclusions
A lower desaturation index in adipose tissue from DD
subjects compared to obese Control subjects and sub-
jects with FML suggests differences in desaturase activ-
ity among the groups. What drives the difference in
desaturase activity is unknown. A potential role of desa-
turase activity in affecting inflammation or lymphatic
dysfunction in DD should be further investigated. The
adipose tissue DIs positively correlate with BMI and
percent body fat in this cohort of RAD and obese non-
RAD subjects. Potential relationships between the DI
and adipokines or adiposity measures in obesity and
RADs should be explored.
Methods
Subjects and adipose tissue collection
Subjects were recruited at the General Clinical Research
Center at the University of California, San Diego
(UCSD) or the VA San Diego Healthcare System
(VASDHS) in two separate research protocols. Subjects
had a diagnosis of DD, MSL, or FML, or were newly
diagnosed (by KLH) using published clinical criteria
[9,16,46] after obtaining a history, performing an exami-
nation and obtaining a fat biopsy from affected adipose
tissue. None of the subjects consumed fish oil supple-
ments. Adipose tissue biopsy samples were obtained
from affected SAT in DD, MSL and FML subjects and
in matched areas in Control subjects using a 5 mm
biopsy needle with intermittent suction as described
previously [23]. We certify that all applicable institu-
tional and governmental regulations concerning the
ethical use of human volunteers were followed during
this research. This study was approved by the Institu-
tional Review Board at UCSD and the Research and
Development Committee at the VASDHS. All subjects
consented to their participation.
Fatty acid extraction from adipose tissue
Samples of adipose tissue weighing 50 mg each were
saponified overnight at 70°C with 100 μl of 30% KOH
(w/v) and 100 μl of 200-proof ethanol. The samples
were then acidified with HCl, and the fatty acids were
extracted with petroleum ether three times and air
dried. This method extracts total fatty acids, including
all fatty acids from triglycerides, cholesteryl esters, phos-
pholipids, and free fatty acids that may be present in the
samples [47]. Fatty acids were derivatized as methyl
esters with 0.5 N methanolic hydrochloric acid (Supelco,
Bellefonte, PA), and dissolved in hexane for GC/MS
analysis.
Gas chromatography/mass spectrometry (GC/MS)
GC/MS analysis was carried out using a Hewlett-Pack-
ard model 5973 selective mass detector connected to a
model 6890 gas chromatograph. 1 μl from each sample
was injected per analysis, and all samples were analyzed
three times. All fatty acids detected in each sample were
separated on the gas chromatograph with a Bpx70 col-
umn (30-m length, 250-μm diameter, 0.25-μmf i l m
thickness) from SGE, Inc. (Austin, TX). The GC condi-
tions were as follows: helium flow rate, 1 ml/min; initial
oven temperature, 150°C, which was programmed to
increase at 3°C/min to a final temperature of 221°C. The
expected retention times for palmitate, palmitoleate,
stearate, oleate, and vaccenate (for example) under these
c o n d i t i o n sw e r ea sf o l l o w s :6 . 6 ,7 . 2 ,9 . 5 ,1 0 . 2 ,a n d1 0 . 3
min, respectively. Mass spectra of fatty acids were
acquired using electron impact ionization. Fatty acids
were identified by comparison of retention time and
mass spectra with known standards.
Desaturation and elongation indices
Desaturation indices were determined by calculating the
ratio of MUFA product to SFA precursor based on the
relative intensities of the gas chromatogram peaks [7,8].
The area under each peak is proportional to the relative
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indices were calculated: palmitoleic/palmitic, oleic/stea-
ric, and vaccenic/stearic. In addition, the ratio of (palmi-
toleic + vaccenic)/palmitic was determined to more
accurately represent the 16-carbon desaturation pathway
s i n c ev a c c e n i ci sa c t u a l l ym a d ef r o me l o n g a t i o no fp a l -
mitoleic acid, and not directly from stearic acid. The
elongation index was determined by calculating the
saturated 18-carbon stearic/16-carbon palmitic ratio
[1,29,38].
Quantitative reverse transcription - PCR analysis
Total RNA was isolated from six subjects with DD, six
subjects with FML (samples were insufficient in two
subjects), five subjects with MSL and six obese Controls
using TRIzol reagent (Invitrogen), according to manu-
facturers instructions. Up to 4 ug of total RNA was
transcribed with Superscript III Synthesis Supermix kit
(Invitrogen). Quantitative real-time PCR was performed
using the Mx3000P Real-time PCR system (Stratagene)
with SYBR Green dye (Molecular Probes) and Platinum
taq polymerase (Stratagene). The primers used and their
sequences are: SCD1 [NM_005063.4] (forward primer 5’
cctagaagctgagaaactggtga 3’ and reverse primer 5’ acatcat-
cagcaagccaggt 3’)a n d1 8s( f o r w a r dp r i m e r5 ’ ggcctcac-
taaaccatccaa 3’ and reverse primer 5’gcaattattccccatgaacg
3’). The levels of PCR product were calculated from
standard curves established for each primer pair.
Other clinical and biochemical measures
Because the samples and data were obtained through
more than one study, complete data was not available
(Table 5). Percent body fat was determined by dual X-ray
absorptiometry scan measurements of fat-free mass and
fat mass for whole body composition (Hologic Discovery
W), and analysis using the software QDR DICOM for
Windows XP. Serum cholesterol, triglyceride (TG), low-
density lipoprotein (LDL), high-density lipoprotein (HDL),
leptin, adiponectin, and non-esterified fatty acid (NEFA)
levels had been determined using commercially available
assay kits. Cholesterol and TG levels were measured by
Trinder-based colorimetric end-point assays (Randox).
LDL and HDL were determined directly by clearance
methods (Randox). NEFA levels were quantified by an
enzymatic colorimetric method using the Wako NEFA-
HR2 kit. Adiponectin and leptin were measured by a mul-
tiplex immunoassay method using the Human Serum Adi-
pokine Panels A, and B, respectively (Millipore).
Statistical analyses
Data analyses were performed using GraphPad Prism 4.0
(GraphPad Software, Inc., San Diego, CA) and SigmaStat
3.5 (Systat Software, San Jose, CA). Differences between
groups were examined with non-parametric two-sample
Wilcoxon (Mann-Whitney) testing. Spearman’sr a n k
order correlations were performed using the desatura-
tion indices and stearic/palmitic ratio against available
clinical and biochemical data on the total cohort of sub-
jects. The correlations against BMI and percent body fat
were also made in males and females separately. All cor-
relations were assessed qualitatively. The authors
acknowledge that correlations made in groups of small
subject numbers may demonstrate increased false-posi-
tive results. Mathematical adjustments for multiple com-
parisons were not done, however, 6 comparisons for
each fatty acid parameter in Tables 2, 3, and 4 were
made, and 83 correlations were performed.
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